Articles tagged with Thrombocytopenia
A phase 2 clinical trial found that 65% of patients receiving avatrombopag met key treatment goals, compared to 17% of those receiving placebo treatment. The oral medication has been shown to be effective in maintaining platelet counts needed to continue chemotherapy as scheduled.
A phase 2 clinical trial shows that mezagitamab can effectively increase platelet counts in patients with immune thrombocytopenia, improving quality of life. The investigational medication has a rapid effect, normalizing platelet counts in 48 hours.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
This study analyzed clinical and pathological characteristics of bone marrow metastasis from non-hematolymphoid malignancies. Prostate and breast carcinomas were the most common malignancies associated with BMM, and anti-neoplastic treatments improved overall survival.
A Phase III clinical trial found that over half of patients who received ianalumab for primary ITP maintained safe platelet counts without serious bleeding episodes for at least one year. The study suggests a new treatment option with the potential to improve long-term quality of life for patients.
A phase III trial found that adding ianalumab to standard therapy extended time to bleeding episodes and improved platelet counts in patients with ITP. The study showed a significant advantage of higher-dose ianalumab over the placebo group, but longer-term durability remains unknown.
Thrombocytopenia is a hallmark of portal hypertension and cirrhosis, with impaired production, increased destruction, and sequestration being key mechanisms. Diagnostic approaches include non-invasive methods like transient elastography and serological markers, while integrated management addresses both PH and thrombocytopenia.
Researchers at University of Pennsylvania discover red blood cells contribute to clot contraction, shrinking and stabilizing blood clots. The finding opens door to new strategies for studying and treating clotting disorders, such as excessive bleeding or dangerous clots like those seen in strokes.
A team of researchers has identified a new chronic blood clotting disorder, VITT-like monoclonal gammopathy of thrombotic significance (MGTS), characterized by antibodies similar to those causing vaccine-induced immune thrombocytopenia and thrombosis (VITT). The disorder can lead to severe symptoms despite treatment with full-dose bloo...
This study investigates the impact of hydrogen sulfide on platelet autophagy in cirrhotic thrombocytopenia and reveals that H2S modulates platelet autophagy via the PDGFR-alpha/PI3K/AKT signaling pathway, which may contribute to thrombocytopenia.
Thrombocytopenia is the third most prevalent symptom of antiphospholipid syndrome, but its cause remains poorly understood. Researchers have unveiled a new mechanism driving thrombocytopenia and identified calprotectin as a potential biomarker for APS-related thrombocytopenia.
Researchers have discovered a link between adenovirus infection and an anti-platelet factor 4 disorder, which can cause severe thrombocytopenia. The condition is rare and potentially fatal, and has been reported in patients with viral symptoms and no exposure to heparin or vaccines.
Researchers found that platelet depletion increased amyloid plaque size and neuronal damage in APP-PS1 mice. However, platelets may have a beneficial role in limiting plaque growth and attenuating neuritic dystrophy at advanced stages of Alzheimer's disease.
A study published in The BMJ found a small increased risk of thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the Covid-19 virus, particularly with adenovirus vaccines. Researchers recommend considering these risks when planning future immunization campaigns and vaccine development.
Researchers at UVA Health System have made a groundbreaking discovery that could boost platelet production on demand to alleviate blood shortages. The finding offers hope for patients with thrombocytopenia and those receiving cord-blood transplants.
Researchers have successfully treated a patient with vaccine-induced thrombotic thrombocytopenia (VITT) using intravenous immunoglobulin concentrates, cortisone, and specific anticoagulants. Prompt diagnosis and treatment can prevent life-threatening thrombosis.
A study in ferrets demonstrates a protective humoral immune response to a weakened form of SFTSV after a single inoculation, and no clinical disease or mortality. The findings suggest potential for this live-attenuated vaccine candidate to provide cross-genotype protection against the emerging virus.
Researchers at CNIO have linked the protein MASTL to a type of inherited thrombocytopenia, which may lead to breakthroughs in cancer metastasis research. They discovered that manipulating other enzymes could potentially reverse the defect and explored its therapeutic potential.
Researchers found that patients with low arginine levels had lower blood platelet counts and impaired immune function. Supplementing arginine in SFTS patients increased platelet production and cleared the virus faster, providing hope for potential treatment targeting this amino acid.
Researchers at Scripps Research have found an enzyme, YRSACT, that increases megakaryocyte production, the precursors to platelets. This discovery offers a new therapeutic option for treating thrombocytopenia, a condition characterized by low platelet counts and increased risk of internal bleeding.
A low-intensity type of laser treatment has been shown to increase platelet production in animals with thrombocytopenia, a potentially life-threatening shortage of blood cells. The therapy also restored platelet levels in mice with autoimmune disorders and chemotherapy-induced thrombocytopenia.
Researchers at CNIO have discovered a new way to produce platelets artificially, reprogramming megakaryocytes to increase in size. This breakthrough could lead to the development of new treatments for thrombocytopenia and cancer by targeting specific proteins involved in cell growth.
A study found that using electron beam sterilized dialyzers increased the risk of thrombocytopenia, a low platelet count associated with bleeding, in hemodialysis patients. The use of non-electron beam sterilized dialyzers reduced this risk.
Scientists have identified a potential new method for replenishing platelet cells, which could treat individuals with low platelet counts. The approach involves infusing mature megakaryocytes into mice, producing functional platelets of normal size and function.
Researchers found a close correlation between vancomycin exposure and severe thrombocytopenia with serious bleeding. The antibiotic was discontinued in most cases, resulting in normal platelet counts.
AkaRx Inc. presents Phase I clinical data of AKR-501, a TPO receptor agonist that mimics the effect of thrombopoietin to stimulate platelet production, with a 50% increase in platelet count in healthy volunteers. The results suggest potential for safe and effective treatment of thrombocytopenia in various diseases.
A new mouse model study identifies the connection between maternal immune activation and reproductive hormone secretion systems, linking them to pregnancy loss. The researchers found that an inflammatory response caused by activated CD40 receptor led to embryo resorption due to decreased progesterone levels.
Two pivotal trials of Zevalin radioimmunotherapy show overall response rates of 80% and 74%, with patients achieving complete responses to therapy. Toxicity was primarily hematologic, transient and reversible.